



[Reference Translation]

November 7, 2024

Company name: JMS Co., Ltd.
Name of representative: Ryuji Katsura, President and Representative Director
(Securities code: 7702; Tokyo Stock Exchange)
Inquiries: Jo Sueda, Executive Officer, Head of Corporate Affairs Division
(Telephone: +81-82-243-5844)

Notice regarding Differences between Consolidated Financial Forecasts and Actual Results for the First Half of the Fiscal Year Ending March 31, 2025 and Revision of Forecast for Consolidated Financial Results for the Full Fiscal Year.

Announcement of the following discrepancies between the consolidated financial results forecast for the first half of the fiscal year ending March 31, 2025 which was announced on May 14, 2024, and the actual results for the same period disclosed today.

In addition, we would like to announce the following revisions made to its forecast for the consolidated financial results for the full fiscal year ending March 31, 2025, in view of the trend in its recent business performance.

1. Difference between Consolidated Financial Forecast and Actual Results for the First Half of the Fiscal Year Ending March 31, 2025 (April 1, 2024 - September 30, 2024)

(Unit: million yen)

	Net sale	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share
Forecast previously announced (A)	34,000	250	250	100	4.08 yen
Actual results announced today (B)	33,830	155	(118)	(258)	(10.56) yen
Difference (B – A)	(169)	(94)	(368)	(358)	
Difference (%)	(0.5)	(37.9)	—	—	
<Reference>Actual results for first half of previous fiscal year ended March 31, 2024	31,248	(320)	(135)	(258)	(10.58) yen

2. Revision to consolidated Financial Forecast for the fiscal year ending March 31, 2025 (April 1, 2024 to March 31, 2025)

(Unit: million yen)

	Net sale	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share
Forecast previously announced (A)	70,000	800	800	400	16.34 yen
Forecast announced today (B)	70,000	700	400	100	4.08 yen
Difference (B – A)	–	(100)	(400)	(300)	
Difference (%)	–	(12.5)	(50.0)	(75.0)	
<Reference> Actual results for previous fiscal year ended March 31, 2024	65,292	(268)	145	(36)	(1.48) yen

3. Reasons for the difference and revision

Net sales for the interim consolidated accounting period of the fiscal year ending March 2025 were generally in line with the previous forecast, due to steady expansion in sales of the Blood Management & Cell Therapy business as a result of a recovery in overseas demand, as well as the Closed Drug Mixing/Infusion Systems business, which we are focusing on as a key business.

Despite the positive impact of increased sales due to growth in core products in Japan and overseas, and the passing on of some price increases, mainly for domestic consumables, the recording of losses on the disposal of inventory assets, and the recording of foreign exchange losses due to the significant adverse impact of foreign exchange rates on non-operating income, operating profit, ordinary profit, and net income attributable to shareholders of the parent company all fell short of the previous forecast.

In addition, with regard to the full-year consolidated earnings forecast for the fiscal year ending March 2025, we have revised the previous earnings forecast, which was announced previously, based on the results of the interim consolidated accounting period and recent trends in the depreciation of the yen and crude oil prices, while continuing to promote earnings improvement through measures such as expanding sales, reviewing prices, reducing manufacturing costs, and reducing expenses through efficient business activities.

*The above forecast is based on currently available information as of the announcement of this material and actual results may differ from the projected figures due to various factors.

END